Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-002008-33
    Sponsor's Protocol Code Number:A6181196
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-03-29
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2011-002008-33
    A.3Full title of the trial
    A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
    STUDIO DI FASE I/II DI SUNITINIB IN PAZIENTI GIOVANI AFFETTI DA TUMORE STROMALE GASTROINTESTINALE IN STADIO AVANZATO
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
    STUDIO DI FASE I/II DI SUNITINIB IN PAZIENTI GIOVANI AFFETTI DA TUMORE STROMALE GASTROINTESTINALE IN STADIO AVANZATO
    A.4.1Sponsor's protocol code numberA6181196
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/035/2009
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPFIZER INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc.,
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc.
    B.5.2Functional name of contact pointClinicalTrials.gov Call Centre
    B.5.3 Address:
    B.5.3.1Street Address235 East 42nd Street
    B.5.3.2Town/ cityNew York
    B.5.3.3Post codeNY 10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number001 800 718 1021
    B.5.5Fax number001 800 718 1021
    B.5.6E-mailClinicalTrials.govCallCenter@pfizer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name SUTENT*30CPS 25MG
    D.2.1.1.2Name of the Marketing Authorisation holderPFIZER ITALIA Srl
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSUNITINIB MALATE
    D.3.9.1CAS number 341031-54-7
    D.3.9.2Current sponsor codeSU011248
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB22366
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name SUTENT*30CPS 12,5MG
    D.2.1.1.2Name of the Marketing Authorisation holderPFIZER ITALIA Srl
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSUNITINIB MALATE
    D.3.9.1CAS number 341031-54-7
    D.3.9.2Current sponsor codeSU011248
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB22366
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number12.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameSunitinib malate
    D.3.2Product code SU011248
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSUNITINIB MALATE
    D.3.9.1CAS number 341031-54-7
    D.3.9.2Current sponsor codeSU011248
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB22366
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number6.25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pediatric Gastro Intestinal Stromal Tumor (GIST)
    Tumore Stromale Gastrointestinale Pediatrico
    E.1.1.1Medical condition in easily understood language
    GIST in young patients
    GIST in giovani pazienti
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level LLT
    E.1.2Classification code 10062427
    E.1.2Term Gastrointestinal stromal tumor
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To characterize the plasma PK profile of sunitinib and its active metabolite SU012662 in children and young adults with advanced (defined as unresectable without major morbidity, metastatic or recurrent) GIST
    • Caratterizzare il profilo farmacocinetico plasmatico di sunitinib e del suo metabolita attivo SU012662 in bambini e giovani adulti con GIST in fase avanzata (definito come non resecabile senza morbilità importanti, metastatico o ricorrente).
    E.2.2Secondary objectives of the trial
    • To investigate whether doses greater than the established pediatric MTD are tolerated in chemotherapy naive pediatric patients with GIST; • To investigate the safety and tolerability of sunitinib in children and young adults with GIST; • To investigate the anti tumor activity of sunitinib in children and young adults with GIST; • To explore PK pharmacodynamic relationships with respect to safety and efficacy in children and young adults with GIST.
    • Valutare se dosi superiori alla MTD pediatrica stabilita siano tollerate dai pazienti pediatrici con GIST mai sottoposti a chemioterapia; • Valutare la sicurezza e la tollerabilità di sunitinib in bambini e giovani adulti con GIST; • Valutare l’attività antitumorale di sunitinib in bambini e giovani adulti con GIST; • Prendere in esame le relazioni farmacocinetiche-frmacodinamiche rispetto a sicurezza ed efficacia in bambini e giovani adulti con GIST.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Histological diagnosis of GIST; 2. KIT genotype (consent for testing sufficient if previous disease progression/intolerance to imatinib); 3. Patients with KIT mutant GIST must have demonstrated either disease progression or intolerance to imatinib mesylate; 4. Age 6 - <21 years; 5. Unresectable without major morbidity, metastatic or recurrent GIST; 6. Measurable (per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1) or evaluable disease; 7. Resolution of all acute toxic effects of prior cancer treatment, radiotherapy or surgical procedure to NCI CTCAE v4.0 grade ≤1; 8. ECOG Performance Status 0-2 (for patients ≥11 years of age) or Lansky ≥50% (for patients <11 years); 9. Adequate organ function determined within 14 days prior to enrollment, defined by: • Peripheral absolute neutrophil count (ANC) ≥1000/μL without growth factor support; • Platelet count ≥100,000/μL (transfusion independent, defined as not receiving platelet transfusions within a 7 days prior to enrollment); • Hemoglobin ≥10 g/dL; • Total bilirubin ≤1.5 x upper limit of normal (ULN) for age; • ALT (SGPT) ≤110 U/L; • Serum albumin ≥2.0 g/dL; • Serum amylase and lipase <1.5 x ULN; • Serum creatinine based on age/gender as follows: Age Maximum Serum Creatinine (mg/dL) Male Female 6 to <10 years 1 1 10 to <13 years 1.2 1.2 13 to <16 years 1.5 1.4 ≥16 years 1.7 1.4 The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC. • Blood Pressure (BP) < the 95th percentile for age, height and gender • Cardiac shortening fraction or ejection fraction greater than the lower limit of normal (LLN) (institutional norm). 10. Evidence of a personally signed and dated informed consent (and where applicable, assent) document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study; 11. Patients (including legal guardian for minors) who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures- 12 Male and female patients of childbearing potential who are sexually active must agree to use a highly effective method of contraception throughout the study and for 30 days after the last after the last sunitinib treatment. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
    1. Diagnosi istologica di GIST; 2. Genotipo KIT (consenso all’esame sufficiente se precedente progressione di malattia/intolleranza a imatinib; vedi Paragrafo 6.1); 3. I pazienti affetti da GIST con mutazioni di KIT devono aver mostrato progressione di malattia o intolleranza a imatinib mesilato; 4. Età compresa tra 6 e &lt;21 anni; 5. GIST non resecabile senza morbilità importanti, metastatico o ricorrente; 6. Malattia misurabile (in base ai Response Evaluation Criteria in Solid Tumors [RECIST] [criteri di valutazione della risposta nei tumori solidi] versione 1.1) o valutabile (vedi Appendice 4); 7. Risoluzione di tutti gli effetti tossici acuti di precedenti trattamenti antitumorali, radioterapia o procedure chirurgiche di grado ≤1 secondo gli NCI CTCAE v4.0; 8. ECOG Performance Status 0-2 (per i pazienti di età ≥11 anni) o Lansky ≥50% (per i pazienti di età &lt;11 anni); 9. Funzione d’organo adeguata determinata entro i 14 giorni precedenti l’arruolamento e definita da: • Conta dei neutrofili assoluta (Absolute Neutrophil Count, ANC) periferica ≥1000 µl senza supporto di fattore di crescita; • Conta piastrinica ≥100.000/µl (trasfusione-indipendente, cioè il paziente non ha ricevuto trasfusioni di piastrine entro i 7 giorni precedenti l’arruolamento); • Emoglobina ≥10 g/dl; • Bilirubina totale ≤1,5 volte il limite superiore di normalità (Upper Limit of Normal, ULN) per l’età; • ALT (SGPT) ≤110 U/l; • Albumina sierica ≥2,0 g/dl; • Amilasi e lipasi sieriche &lt;1,5 volte l’ULN; • Creatinina sierica basata su età/sesso come segue: Età Creatinina sierica massima (mg/dl) Maschi Femmine da 6 a &lt;10 anni 1 1 da 10 a &lt;13 anni 1,2 1,2 da 13 a &lt;16 anni 1,5 1,4 ≥16 anni 1,7 1,4 I valori soglia per la creatinina in questa tabella sono stati ottenuti con la formula di Schwartz per la GFR stimata (Schwartz et al. J Peds, 106:522, 1985)27 utilizzando i dati di lunghezza e statura del bambino pubblicati dai CDC. • Pressione arteriosa (PA) &lt;95° percentile per età, statura e sesso (vedi Appendice 3 per gli intervalli pediatrici); • Frazione di accorciamento o frazione di eiezione superiore al limite inferiore di normalità (Lower Limit of Normal, LLN) (norma istituzionale). 10. Documento di consenso informato (e, dove applicabile, di assenso) personalmente firmato e datato nel quale si dimostra che il paziente (o un suo rappresentante legalmente accettabile) è stato informato di tutti gli aspetti pertinenti dello studio; 11. Pazienti (compreso il tutore legale di un minore) consenzienti e in grado di rispettare le visite programmate, il piano di trattamento, gli esami di laboratorio e le altre procedure dello studio; 12. I pazienti di sesso maschile e femminile in età fertile sessualmente attivi devono acconsentire ad adottare un metodo contraccettivo altamente efficace durante tutto il periodo di studio e per 30 giorni dopo l’ultimo trattamento con sunitinib. Un paziente è in età fertile se, a giudizio del ricercatore, è biologicamente in grado di avere bambini ed è sessualmente attivo
    E.4Principal exclusion criteria
    Patients presenting with any of the following will not be included in the study: 1. Current treatment with another investigational agent and/or systemic anti-cancer therapy within 4 weeks before starting sunitinib treatment; 2. Prior sunitinib treatment; 3. Prior therapy with known risk for cardiovascular complications, eg, prior radiation therapy that included the heart (cardiac silhouette) and/or craniospinal radiation; Patients with prior anthracycline exposure may be included if the total cumulative exposure was ≤150mg/m2; 4. Concomitant treatment with any drug having proarrhythmic potential (terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide); 5. Prior diagnosis of cardiac disease, including, but not limited to: • Ongoing cardiac dysrhythmias of NCI CTCAE v4.0 ≥ grade 2, atrial fibrillation of any grade; • QTc interval >450 msec for males or >470 msec for females; • Hypertension that cannot be controlled by medications; • Any of the following within the 12 months prior to starting study treatment: congestive heart failure, cerebrovascular accident including transient ischemic attack or pulmonary embolism. 6. Grade ≥3 hemorrhage within 4 weeks prior to study entry; 7. Current treatment with therapeutic doses of coumarin derivative anticoagulants such as warfarin or anti vitamin K agents; 8. Concurrent administration of strong cytochrome P450-3A (CYP3A4) inhibitor(s) and/or inducer(s) within 7 and 12 days prior to study entry, respectively; 9. Prior radiation to >25% of the bone marrow; 10. Patients with history of allergic reaction attributed to sunitinib or any component of sunitinib capsules; 11. Pregnant females; breastfeeding females; males and females of childbearing potential; males and females of childbearing potential not using highly effective contraception or not agreeing to continue highly effective contraception for 30 days after last dose of investigational product; males and females of childbearing potential not using two (2) methods of highly effective contraception or not agreeing to continue two (2) methods of highly effective contraception for 30 days after last dose of investigational product; 12. Active infection, or receiving antiretroviral therapy for HIV disease; 13. Patients who are investigational site staff members or relatives of those site staff members or patients who are Pfizer employees directly involved in the conduct of the trial; 14. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
    1.Trattamento in corso con un altro farmaco sperimentale e/o terapia antitumorale sistemica entro le 4 settimane precedenti l’inizio del trattamento con sunitinib; 2. Precedente trattamento con sunitinib; 3. Pregressa terapia con rischio noto di complicanze cardiovascolari, p.es. precedente radioterapia cardiaca (silhouette cardiaca) e/o cranica; i pazienti con precedente esposizione ad antraciclina possono essere inclusi se l’esposizione cumulativa totale è stata ≤150 mg/m2; 4. Trattamento concomitante con qualsiasi farmaco dotato di potenziale proaritmico (terfenadina, chinidina, procainamide, disopiramide, sotalolo, probucol, bepridil, aloperidolo, risperidone, indapamide e flecainide); 5. Precedente diagnosi di cardiopatia, compresi, ma non limitatamente a: • Disritmie cardiache in atto di grado ≥2 secondo gli NCI CTCAE v4.0, fibrillazione atriale di qualsiasi grado; • Intervallo QTc &lt;450 msec per i maschi e &gt;470 msec per le femmine; • Ipertensione non controllata farmacologicamente; • Uno qualsiasi dei seguenti entro i 12 mesi precedenti l’inizio del trattamento in studio: scompenso cardiaco congestizio, accidente cerebrovascolare, compresi attacco ischemico transitorio o embolia polmonare. 6. Emorragia di grado ≥3 le 4 settimane precedenti l’ingresso nello studio; 7. Trattamento in corso a dosi terapeutiche con anticoagulanti derivati dal coumarin come warfarin o agenti antivitamina K; 8. Somministrazione contemporanea di un potente(i) inibitore(i) e/o induttore(i) del citocromo P450-3A (CYP3A4) entro i 7 e i 12 giorni precedenti l’ingresso nello studio, rispettivamente (vedi Paragrafo 5.5.2); 9. Precedente irradiazione di &gt;25% del midollo osseo; 10. Pazienti con anamnesi di reazioni allergiche attribuite a sunitinib o a qualsiasi componente delle capsule di sunitinib; 11. Donne in gravidanza; donne in allattamento, maschi e femmine in età fertile; maschi e femmine in età fertile che non adottano metodi contraccettivi altamente efficaci o non acconsentono a continuare l’uso di metodi contraccettivi altamente efficaci nei 30 giorni successivi all’ultima dose del prodotto sperimentale; maschi e femmine in età fertile che non adottano due (2) metodi contraccettivi altamente efficaci o non acconsentono a continuare l’uso dei due (2) metodi contraccettivi altamente efficaci nei 30 giorni successivi all’ultima dose del prodotto sperimentale (vedi Paragrafo 4.3); 12. Infezione in atto o in trattamento con terapia antiretrovirale per HIV; 13. Pazienti membri o parenti di membri del personale di ricerca del sito oppure pazienti dipendenti Pfizer direttamente coinvolti nella conduzione dello studio clinico; 14. Altra grave condizione medica o psichiatrica acuta o cronica oppure anomalie di laboratorio che possono incrementare il rischio associato alla partecipazione allo studio o alla somministrazione del prodotto sperimentale oppure interferire con l’interpretazione dei risultati e, a giudizio del ricercatore, renderebbero il paziente non idoneo all’ingresso in questo studio
    E.5 End points
    E.5.1Primary end point(s)
    Pharmacokinetic parameters of sunitinib and its main active metabolite (SU012662) including total plasma exposure (AUC24) and oral clearance (CL/F).
    Parametri di farmacococinetica del sunitinib e dei suoi metaboliti attivi (SU012662) inclusa l’area sotto la curva delle concentrazioni plasmatiche in funzione del tempo (AUC24) e la clearance orale (CL/F)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Descriptive statistics for observed and dose-corrected (where appropriate) PK data will be reported for all patients with at least one PK observation by presenting the population size, arithmetic mean, standard deviation, percent coefficient of variation (CV%), median, minimum, maximum values at the end of the study.
    La descrizione statistica per i dati di PK osservati e dose correlati (dove applicabili) saranno riportati per tutti i pazienti con almeno un'osservazione di PK presentando la grandezza della popolazione, la media aritmetica, la deviazione standard, il coefficiente di variazione %, la mediana, il minimo e massimo valore alla fine dello studio.
    E.5.2Secondary end point(s)
    • Type, incidence, severity (graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0 [v4.0]), timing, seriousness, and relatedness of adverse events and laboratory abnormalities; • Objective response rate, duration of response, PFS and OS at 2 years after study enrollment; • Pharmacokinetic pharmacodynamic relationships with respect to safety and efficacy in pediatric GIST
    Tipologia, incidenza e severità (in accordo al NCI Criteri per la -Terminologia Comune per gli Eventi Avversi (CTCAE), Versione 4.0 (V4.0), tempi serietà e correlazione degli eventi e anomalie di laboratorio - tasso della risposta obiettiva,durata della risposta, PFS e OS a 2 anni dopo l'arruolamento - relazione fra farmacocinetica e farmacodinamica con riferimento alla sicurezza e efficacia in pediatrici GIST
    E.5.2.1Timepoint(s) of evaluation of this end point
    At the end of the study.
    alla fine dello studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence Yes
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    PK profile in children
    Profilo di farmacocinetica nei bambini
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised Information not present in EudraCT
    E.8.1.2Open Information not present in EudraCT
    E.8.1.3Single blind Information not present in EudraCT
    E.8.1.4Double blind Information not present in EudraCT
    E.8.1.5Parallel group Information not present in EudraCT
    E.8.1.6Cross over Information not present in EudraCT
    E.8.1.7Other Information not present in EudraCT
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Information not present in EudraCT
    E.8.2.2Placebo Information not present in EudraCT
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA29
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Brazil
    Canada
    Chile
    Egypt
    Jordan
    Mexico
    Turkey
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Trial in all participating countries is defined as collection of the final data point in the study. Because this clinical trial includes a survival endpoint, the last data point is anticipated to be the last survival follow-up (i.e., date last known alive or of death) prior to the cutoff date for database lock for the final Clinical Study Repor
    La fine dello studio in tutti i Paesi è la raccolta dell'end point finale.Dal momento che c'è un endpoint di sopravvivenza, l'ultimo dato sarà quello raccolto per la sopravv. prima del cutoff per la chiusura del database per il Clin Study Report
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years7
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years7
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 15
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 3
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 12
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 15
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Pediatric Patients
    pazienti pediatrici
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 12
    F.4.2.2In the whole clinical trial 30
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    as for protocol
    come da protocollo
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-03-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-02-14
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 17:47:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA